Showing 3701-3710 of 5693 results for "".
- Regenxbio Reports Positive Phase 2 Data on ABBV-RGX-314 for Bilateral Wet AMDhttps://modernod.com/news/regenxbio-reports-positive-phase-2-data-on-abbv-rgx-314-for-bilateral-wet-amd/2482503/Regenxbio announced results from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314, a gene therapy candidate, in patients with bilateral wet age-related macular degeneration (AMD). The data was presented at the American Academy of Ophthalmology (AAO) me
- Google’s Diabetic Retinopathy AI Model Licensed for Use in India and Thailandhttps://modernod.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/Google announced the licensing of its diabetic retinopathy artificial intelligence (AI) model to healthcare providers and health-tech partners. According to Google, during the next 10 years, Forus Health, AuroLab, and Perceptra will aim to deliver a combined 6 million AI-supported scree
- Glaukos Announces Positive Phase 3 Results for Epioxa Corneal Cross-Linking Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-results-for-epioxa-corneal-cross-linking-therapy/2482495/Glaukos announced that its second phase 3 confirmatory pivotal trial for Epioxa (Epi-on), a next-generation corneal cross-linking therapy for the treatment of keratoconus, has met its primary efficacy endpoint. The trial demonstrated a statistically significant and clinically
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- FDA Approves Bausch + Lomb's enVista Envy Full Range of Vision IOLhttps://modernod.com/news/bausch-lomb-announces-fda-approval-of-envista-envy-full-range-of-vision-iol/2482482/Bausch + Lomb announced that the FDA has approved the enVista Envy full range of vision IOL. The new lens is built on the enVista IOL platform and is designed to offer patients a continuous range of vision while providing excellent tolerance for dysphotopsia.
- RetinaLyze Launches Advanced Glaucoma Progression AIhttps://modernod.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/RetinaLyze has introduced the Advanced Glaucoma Progression AI. Central to this technology is the 'Glaucoma Index of Progression' (GIP), a tool designed to provide a stable and consistent method for tracking glaucoma progression over time. Glaucoma, often referred to a
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300